about
Transcatheter aortic valve implantation complicated by acute pericardial tamponade.The role of invasive diagnostics and its impact on the treatment of dilated cardiomyopathy: A systematic review.Viral Infection of the Heart: Pathogenesis and Diagnosis.Viral heart disease - treatment.Viral Nucleic Acids in the Serum Are Dependent on Blood Sampling Site in Patients with Clinical Suspicion of Myocarditis.Impella LD microaxial pump supporting combined mitral and coronary surgery in a patient with dilated cardiomyopathy. A short bridge to recovery?An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil.Viral heart disease and acute coronary syndromes - often or rare coexistence ?Changes in desmin expression in patients with cardiac diastolic dysfunction and preserved or reduced ejection fraction.Type of desmin expression in cardiomyocytes - a good marker of heart failure development in idiopathic dilated cardiomyopathy.Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - ARNIs in patients with heart failure with reduced left ventricular ejection fraction in Poland.Right ventricular morphology and function is not related with microRNAs and fibrosis markers in dilated cardiomyopathy.Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy.Kardiologiczna manifestacja zespołu MELAS wywołana mutacją mDNA w pozycji 3243The proposed new classification of coronary microcirculation as the predictor of the heart failure progression in idiopathic dilated cardiomyopathy[A large symptomatic pericardial cyst][The first LENUS pro® pump implantation in Poland in patient with pulmonary hypertension]Viral heart diseasePatterns of desmin expression in idiopathic dilated cardiomyopathy are related to the desmin mRNA and ubiquitin expression
P50
Q33555482-90D0A967-B33C-40A2-AB6A-52C95E772679Q38944947-1476F989-2F4C-4331-AE74-894CC51B194BQ40111995-14CC62FE-61E3-4D74-B571-ED8AC990CCEBQ40120206-D844F76E-D3E7-4B8C-A526-E999DF2B9256Q40374408-B351A704-307D-4197-89AD-0B439C8A46CBQ42120521-7F954EEC-3AAC-47EB-B359-F32D5F7CF1C0Q47110514-2A4E61BE-AC93-428D-9EF3-D28C0D395240Q47560039-5E7C8760-DD9F-440B-9837-E80AA347D00AQ48300922-C5C34758-AD5A-493A-AF29-AD5E11C28D50Q48682978-7F034DE9-9CC0-441B-9FB4-7D340A783DC0Q49382960-6DA5A7FF-FE05-4F39-BD2F-C5AFA6E95F47Q51801205-4A136566-7B58-4A5D-9B05-08F3973F7FE0Q52954172-19E37010-FB6D-49A7-935D-3DD72B511ABBQ59697388-2FAB6F5C-9EA3-48E7-926D-145D619EDFEDQ86185085-8A9322B9-90EF-4B3A-8005-744F330ED80AQ87009281-ACED9716-8C4B-4EDD-9E56-8D6221CA75C3Q89041947-BBB4E8F4-F630-49E4-A974-D6470A55CCB1Q89263751-B1649AD8-4209-435D-BC51-44F5ED9CB075Q90878490-2DEB569D-91EE-49EA-A30C-FBBED05603D3
P50
description
researcher (ORCID 0000-0001-9032-9130)
@en
wetenschapper
@nl
name
A Pawlak
@en
A Pawlak
@nl
type
label
A Pawlak
@en
A Pawlak
@nl
prefLabel
A Pawlak
@en
A Pawlak
@nl
P31
P496
0000-0001-9032-9130